Biologics Market Forecast Report, 2016-2024
Biologics are at the forefront of science and support the most recent scientific breakthroughs. Such breakthroughs are expected to lead to innovative treatments that provide options to patients with new treatment methods. A biologic medicine (biologic) is a medication made from living organisms or containing components of living organism. For the making of new biologics, new innovations and innovative treatments are evolving, indicating that the global biologics market is likely to exhibit bright future outlook. Biologics are commonly used to treat, detect, and heal a broad range of illnesses, including infectious diseases, autoimmune conditions, chronic kidney failure, and cancer. Wide application of the product is estimated to foster expansion of the global biologics market in the years to come.
In addition to that, a better comprehension of disease's molecular and genetic origin has paved the way for the advancement of a variety of tailored therapies. Recombinant proteins, for example, help support the immune system in identifying and attaching foreign substances.
Biologics are anticipated to rise significantly in the coming years, due to the decline in productivity of small molecule drug R&D. In order to retain their market share, pharmaceutical firms are working on the production of many biopharmaceutical drugs. More moderate patients are expected to switch to branded and novel therapies when oral drugs for Crohn's disease and rheumatoid arthritis improve in effectiveness. Furthermore, novel molecules provide therapeutic alternatives for patients who have previously failed to respond to conventional therapies, and they often demonstrate superior protection and effectiveness.
Biopharmaceutical production capability is expected to increase as processing capacities improve. The utilization of single-use technologies in the manufacturing and production of biopharmaceuticals is another instance of these developments. In addition to that, biologists are researching on more efficient organisms and speech mechanisms. Revenue generation is expected to be fueled by the invention of cell lines and reagents that improve the efficacy of biological products.
Manufacturing is one of the most important processes in the production of biologics, accounting for a large slice of the global biologics market. The mode of production is an essential factor to examine since it symbolizes the sector's outsourcing and in-house operations. Businesses are preferring to make rather than acquire or outsource services. This has resulted in a higher percentage of biologics being manufactured in-house. Businesses are investing in their own bioprocessing capabilities.
CMOs are making investments to expand their commercial biopharmaceutical production capability. However, the value of outsourcing contracts is lower than the overall market, and they will not be able to drive sector expansion like they do in the pharmaceutical industry. As a result of the increased prevalence of cancer combined with the presence of many R&D programs, oncology accounted for the greatest percentage. For cancer eradication, these initiatives include gene treatments and antisense medicines.
Oncology is also expected to continue its dominance in the during the projection period. The increased use of the product to lessen the number of adverse effects connected with the use of cancer chemotherapy is one of the key drivers for the predicted growth.
Due to the existence of substantial established companies in this area, North America is likely to lead in terms of revenue generation. Furthermore, a bigger revenue share is attributable to increasing demand for disease-treatment items. Furthermore, pharmaceutical corporations in the U.S are responsible for 80% of global R&D in healthcare biotechnology. In North America, the aforementioned aspect is expected to drive expansion of the biologics market in the years to come.
Asian contract manufacturers have poured money into the market to gain a foothold in the capital-intensive business. In Asia, companies like Samsung Biologics and Wuxi Biologics are expected to drive growth of the regional market over the forecast period.
Biologics market is expected to reach the value of US$479, 752 million by the end of 2024
Biologics market is anticipated to expand at a CAGR of 10.9% during the forecast period
Biologics market is driven by intensive R&D activities, innovative drug formulations, and a large number of clinical trials focused on large-molecule drug discovery
The monoclonal antibodies segment is expected to lead the biologics market along the forecast period
Top key players in biologics market are AbbVie Inc., AstraZeneca, Amgen Inc., F. Hoffmann-La Roche Ltd, Bayer AG, Sanofi, Eli Lilly and Company, GlaxoSmithKline Plc., Pfizer Inc., Merck & Co., Inc., and Novartis AG
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary : Global Biologics Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.2. Overview
4.3. Market Opportunity Map
4.4. Market Dynamics
4.4.1. Drivers
4.4.2. Restraints
4.4.3. Opportunity
4.5. Global Biologics Market Analysis and Forecasts, 2014–2024
4.5.1. Porter’s Analysis
4.5.2. Supply Chain Analysis
4.5.2.1. Product Manufacturers
4.5.2.2. Product Distributors
4.5.2.3. End Users
4.5.3. Market Revenue Projections (US$ Mn)
4.9. Market Outlook
5. Global Biologics Market Analysis and Forecasts, By Product
5.1. Introduction & Definition
5.2. Key Findings / Developments
5.3. Global Biologics Market Value Share Analysis
5.4. Market Value Forecast By Product , 2014–2024
5.4.1. Monoclonal Antibodies
5.4.2. Vaccines
5.4.3. Recombinant Hormones/Proteins
5.4.4. Cell Therapy
5.4.5. Gene Therapy
5.4.6. Others
5.5. Market Attractiveness By Product
6. Global Biologics Market Analysis and Forecasts, By Application
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Global Biologics Market Value Share Analysis
6.4. Market Value Forecast By Application , 2014–2024
6.4.1. Oncology
6.4.2. Infectious Diseases
6.4.3. Immunology
6.4.4. Autoimmune Diseases
6.4.5. Others
6.5. Market Attractiveness By Application
7. Global Biologics Market Analysis and Forecasts, By Region
7.1. Key Findings
7.2. Global Growth Scenario
7.3. Market Value Forecast By Region
7.3.1. North America
7.3.2. Europe
7.3.3. Asia Pacific
7.3.4. Latin America
7.3.5. MEA
7.4. Market Attractiveness By Country/Region
8. North America Biologics Market Analysis and Forecast
8.1. Introduction/ Key findings
8.2. Market Value Forecast By Product , 2014–2024
8.2.1. Monoclonal Antibodies
8.2.2. Vaccines
8.2.3. Recombinant Hormones/Proteins
8.2.4. Cell Therapy
8.2.5. Gene Therapy
8.2.6. Others
8.3. Market Value Forecast By Application , 2014–2024
8.3.1. Oncology
8.3.2. Infectious Diseases
8.3.3. Immunology
8.3.4. Autoimmune Diseases
8.3.5. Others
8.4. Market Value Forecast By Country , 2014–2024
8.4.1. US
8.4.2. Canada
8.5. Market Attractiveness Analysis
8.5.1. By Product
8.5.2. By Application
8.5.3. By Country
9. Europe Biologics Market Analysis and Forecast
9.1. Introduction/Key Findings
9.2. Market Value Forecast By Product , 2014–2024
9.2.1. Monoclonal Antibodies
9.2.2. Vaccines
9.2.3. Recombinant Hormones/Proteins
9.2.4. Cell Therapy
9.2.5. Gene Therapy
9.2.6. Others
9.3. Market Value Forecast By Application , 2014–2024
9.3.1. Oncology
9.3.2. Infectious Diseases
9.3.3. Immunology
9.3.4. Autoimmune Diseases
9.3.5. Others
9.4. Market Value Forecast By Country , 2014–2024
9.4.1. Germany
9.4.2. UK
9.4.3. Spain
9.4.4. France
9.4.5. Italy
9.4.6. Rest of Europe
9.5. Market Attractiveness Analysis
9.5.1. By Product
9.5.2. By Application
9.5.3. By Country
10. Asia Pacific Biologics Market Analysis and Forecast
10.1. Introduction/Key Findings
10.2. Market Value Forecast By Product , 2014–2024
10.2.1. Monoclonal Antibodies
10.2.2. Vaccines
10.2.3. Recombinant Hormones/Proteins
10.2.4. Cell Therapy
10.2.5. Gene Therapy
10.2.6. Others
10.3. Market Value Forecast By Application , 2014–2024
10.3.1. Oncology
10.3.2. Infectious Diseases
10.3.3. Immunology
10.3.4. Autoimmune Diseases
10.3.5. Others
10.4. Market Value Forecast By Country , 2014–2024
10.4.1. India
10.4.2. China
10.4.3. Japan
10.4.4. Australia
10.4.5. New Zealand
10.4.6. Rest of Asia Pacific
10.5. Market Attractiveness Analysis
10.5.1. By Product
10.5.2. By Application
10.5.3. By Country
11. Latin America Biologics Market Analysis and Forecast
11.1. Introduction/Key Findings
11.2. Market Value Forecast By Product , 2014–2024
11.2.1. Monoclonal Antibodies
11.2.2. Vaccines
11.2.3. Recombinant Hormones/Proteins
11.2.4. Cell Therapy
11.2.5. Gene Therapy
11.2.6. Others
11.3. Market Value Forecast By Application , 2014–2024
11.3.1. Oncology
11.3.2. Infectious Diseases
11.3.3. Immunology
11.3.4. Autoimmune Diseases
11.3.5. Others
11.4. Market Value Forecast By Country , 2014–2024
11.4.1. Brazil
11.4.2. Mexico
11.4.3. Rest of LATAM
11.5. Market Attractiveness Analysis
11.5.1. By Product
11.5.2. By Application
11.5.3. By Country
12. MEA Biologics Market Analysis and Forecast
12.1. Introduction/Key Findings
12.2. Market Value Forecast By Product , 2014–2024
12.2.1. Monoclonal Antibodies
12.2.2. Vaccines
12.2.3. Recombinant Hormones/Proteins
12.2.4. Cell Therapy
12.2.5. Gene Therapy
12.2.6. Others
12.3. Market Value Forecast By Application , 2014–2024
12.3.1. Oncology
12.3.2. Infectious Diseases
12.3.3. Immunology
12.3.4. Autoimmune Diseases
12.3.5. Others
12.4. Market Value Forecast By Country , 2014–2024
12.4.1. South Africa
12.4.2. Saudi Arabia
12.4.3. UAE
12.4.4. Rest of MEA
12.5. Market Attractiveness Analysis
12.5.1. By Product
12.5.2. By Application
12.5.3. By Country
13. Competition Landscape
13.1. Market Player – Competition Dashboard (By Tier and Size of companies)
13.2. Blockbuster Drug Matrix
13.3. Pipeline snapshot of Key Biological Therapies
13.4. Company Profiles
13.4.1. AbbVie Inc.
13.4.1.1. Company Overview
13.4.1.2. Financials
13.4.1.3. SWOT Analysis
13.4.1.4. Strategic Overview
13.4.2. Amgen Inc.
13.4.2.1. Company Overview
13.4.2.2. Financials
13.4.2.3. SWOT Analysis
13.4.2.4. Strategic Overview
13.4.3. AstraZeneca
13.4.3.1. Company Overview
13.4.3.2. Financials
13.4.3.3. SWOT Analysis
13.4.3.4. Strategic Overview
13.4.4. Bayer AG
13.4.4.1. Company Overview
13.4.4.2. Financials
13.4.4.3. SWOT Analysis
13.4.4.4. Strategic Overview
13.4.5. Eli Lilly and Company
13.4.5.1. Company Overview
13.4.5.2. Financials
13.4.5.3. SWOT Analysis
13.4.5.4. Strategic Overview
13.4.6. F. Hoffmann-La Roche Ltd.
13.4.6.1. Company Overview
13.4.6.2. Financials
13.4.6.3. SWOT Analysis
13.4.6.4. Strategic Overview
13.4.7. GlaxoSmithKline Plc.
13.4.7.1. Company Overview
13.4.7.2. Financials
13.4.7.3. SWOT Analysis
13.4.7.4. Strategic Overview
13.4.8. Johnson & Johnson Services, Inc.
13.4.8.1. Company Overview
13.4.8.2. Financials
13.4.8.3. SWOT Analysis
13.4.8.4. Strategic Overview
13.4.9. Merck & Co., Inc.
13.4.9.1. Company Overview
13.4.9.2. Financials
13.4.9.3. SWOT Analysis
13.4.9.4. Strategic Overview
13.4.10. Novartis AG
13.4.10.1. Company Overview
13.4.10.2. Financials
13.4.10.3. SWOT Analysis
13.4.10.4. Strategic Overview
13.4.11. Pfizer Inc.
13.4.11.1. Company Overview
13.4.11.2. Financials
13.4.11.3. SWOT Analysis
13.4.11.4. Strategic Overview
13.4.12. Sanofi
13.4.12.1. Company Overview
13.4.12.2. Financials
13.4.12.3. SWOT Analysis
13.4.12.4. Strategic Overview
List of Tables
Table 01: Global Biologics Market Size (US$ Mn) Forecast: by Product, 2016–2024
Table 02: Global Biologics Market Size (US$ Mn) Forecast: by Applications, 2016–2024
Table 03: Global Biologics Market Size (US$ Mn) Forecast: by Region, 2016-2024
Table 04: North America Biologics Market Size (US$ Mn) Forecast: by Product, 2016-2024
Table 05: North America Biologics Market Size (US$ Mn) Forecast: by Applications, 2016–2024
Table 06: North America Biologics Market Size (US$ Mn) Forecast: by Country, 2016-2024
Table 07: Europe Biologics Market Size (US$ Mn) Forecast: by Product, 2016-2024
Table 08: Europe Biologics Market Size (US$ Mn) Forecast: by Applications, 2016–2024
Table 09: Europe Biologics Market Size (US$ Mn) Forecast: by Country, 2016-2024
Table 10: Asia Pacific Biologics Market Size (US$ Mn) Forecast: by Product, 2016-2024
Table 11: Asia Pacific Biologics Market Size (US$ Mn) Forecast: by Applications, 2016–2024
Table 12: Asia Pacific Biologics Market Size (US$ Mn) Forecast: by Country, 2016-2024
Table 13: Latin America Biologics Market Size (US$ Mn) Forecast: by Product, 2016-2024
Table 14: Latin America Biologics Market Size (US$ Mn) Forecast: by Applications, 2016–2024
Table 15: Latin America Biologics Market Size (US$ Mn) by Country, 2016–2024
Table 16: Middle East and Africa Biologics Market Size (US$ Mn) Forecast: by Product, 2016-2024
Table 17: Middle East and Africa Biologics Market Value (US$ Mn) Forecast: by Applications, 2016–2024
Table 18: Middle East & Africa Biologics Market Size (US$ Mn) Forecast: by Country, 2016–2024
List of Figures
Figure 01: Global Biologics Market Size (US$ Mn) Forecast, 2016–2024
Figure 02: Global Biologics Market Absolute $ Opportunity (US$ Mn), 2016?2024
Figure 03: Global Biologics Market Value Share Analysis: by Product, 2016 and 2024
Figure 04: Global Biologics Market Value (US$ Mn) and Y-o-Y Growth (%), 2016–2024
Figure 05: Global Biologics Market Value (US$ Mn) and Y-o-Y Growth (%), 2016–2024
Figure 06: Global Biologics Market Value (US$ Mn) and Y-o-Y Growth (%), 2016–2024
Figure 07: Global Biologics Market Value (US$ Mn) and Y-o-Y Growth (%), 2016–2024
Figure 08: Global Biologics Market Value (US$ Mn) and Y-o-Y Growth (%), 2016–2024
Figure 09: Global Biologics Market Value (US$ Mn) and Y-o-Y Growth (%), 2016–2024
Figure 10: Global Biologics Market Attractiveness Analysis: by Product
Figure 11: Global Biologics Market Value Share Analysis: by Applications, 2016 and 2024
Figure 12: Global Biologics Market Value (US$ Mn) and Y-o-Y Growth (%), 2016–2024
Figure 13: Global Biologics Market Value (US$ Mn) and Y-o-Y Growth (%), 2016–2024
Figure 14: Global Biologics Market Value (US$ Mn) and Y-o-Y Growth (%), 2016–2024
Figure 15: Global Biologics Market Value (US$ Mn) and Y-o-Y Growth (%), 2016–2024
Figure 16: Global Biologics Market Value (US$ Mn) and Y-o-Y Growth (%), 2016–2024
Figure 17: Global Biologics Market Attractiveness Analysis: by Applications
Figure 18: Global Biologics Market Value Share Analysis: by Region, 2016 and 2024
Figure 19: Global Biologics Market Attractiveness Analysis: by Region
Figure 20: North America Biologics Market Size (US$ Mn) Forecast, 2016-2024
Figure 21: North America Biologics Market Size and Y-o-Y Growth Projections, 2016-2024
Figure 22: North America Biologics Market Attractiveness Analysis: by Country
Figure 23: North America Biologics Market Value Share Analysis: by Product, 2016 and 2024
Figure 24: North America Biologics Market Value Share Analysis: by Applications, 2016 and 2024
Figure 25: North America Biologics Market Value Share Analysis: by Country, 2016 and 2024
Figure 26: U.S. Biologics Market Size (US$ Mn) Forecast, 2016-2024
Figure 27: U.S. Biologics Market Absolute $ Opportunity (US$ Mn), 2016-2024
Figure 28: Canada Biologics Market Size (US$ Mn) Forecast, 2016-2024
Figure 29: Canada Biologics Market Absolute $ Opportunity (US$ Mn), 2016-2024
Figure 30: North America Biologics Market Forecast: by Product, 2016–2024
Figure 31: North America Biologics Market Forecast: by Application, 2016–2024
Figure 32: Europe Biologics Market Size (US$ Mn) Forecast, 2016-2024
Figure 33: Europe Biologics Y-o-Y Growth Projections, 2016-2024
Figure 34: Europe Market Attractiveness Analysis: by Country
Figure 35: Europe Biologics Market Value Share Analysis: by Product, 2016 and 2024
Figure 36: Europe Biologics Market Value Share Analysis: by Applications, 2016 and 2024
Figure 37: Europe Biologics Market Value Share Analysis: by Country, 2016 and 2024
Figure 38: Germany Biologics Market Size (US$ Mn) Forecast, 2016-2024
Figure 39: Germany Biologics Market Absolute $ Opportunity (US$ Mn), 2016-2024
Figure 40: U.K. Biologics Market Size (US$ Mn) Forecast, 2016-2024
Figure 41: U.K. Biologics Market Absolute $ Opportunity (US$ Mn), 2016-2024
Figure 42: France Biologics Market Size (US$ Mn) Forecast, 2016-2024
Figure 43: France Biologics Market Absolute $ Opportunity (US$ Mn), 2016-2024
Figure 44: Italy Biologics Market Size (US$ Mn) Forecast, 2016-2024
Figure 45: Italy Biologics Market Absolute $ Opportunity (US$ Mn), 2016-2024
Figure 46: Spain Biologics Market Size (US$ Mn) Forecast, 2016-2024
Figure 47: Spain Biologics Market Absolute $ Opportunity (US$ Mn), 2016-2024
Figure 48: Rest of Europe Biologics Market Size (US$ Mn) Forecast, 2016-2024
Figure 49: Rest of Europe Biologics Market Absolute $ Opportunity (US$ Mn), 2016-2024
Figure 50: Europe Biologics Market Forecast By Product Type, 2016–2024
Figure 51: Europe Biologics Market Forecast By Application, 2016–2024
Figure 52: Asia Pacific Biologics Market Size (US$ Mn) Forecast, 2016-2024
Figure 53: Asia Pacific Biologics Market Size and Y-o-Y Growth Projections, 2016-2024
Figure 54: Asia Pacific Biologics Market Attractiveness Analysis: by Country, 2016-2024
Figure 55: Asia Pacific Biologics Market Value Share Analysis: by Product, 2016 and 2024
Figure 56: Asia Pacific Biologics Market Value Share Analysis: by Applications, 2016 and 2024
Figure 57: Asia Pacific Biologics Market Value Share Analysis: by Country, 2016 and 2024
Figure 58: China Biologics Market Size (US$ Mn) Forecast, 2016-2024
Figure 59: China Biologics Market Absolute $ Opportunity (US$ Mn), 2016-2024
Figure 60: Japan Biologics Market Size (US$ Mn) Forecast, 2016-2024
Figure 61: Japan Biologics Market Absolute $ Opportunity (US$ Mn), 2016-2024
Figure 62: India Biologics Market Size (US$ Mn) Forecast, 2016-2024
Figure 63: India Biologics Market Absolute $ Opportunity (US$ Mn), 2016-2024
Figure 64: Australia Biologics Market Size (US$ Mn) Forecast, 2016-2024
Figure 65: Australia Biologics Market Absolute $ Opportunity (US$ Mn), 2016-2024
Figure 66: New Zealand Biologics Market Size (US$ Mn) Forecast, 2016-2024
Figure 67: New Zealand Biologics Market Absolute $ Opportunity (US$ Mn), 2016-2024
Figure 68: Rest of APAC Biologics Market Size (US$ Mn) Forecast, 2016-2024
Figure 69: Rest of APAC Biologics Market Absolute $ Opportunity (US$ Mn), 2016-2024
Figure 70: Asia Pacific Biologics Market Attractiveness Analysis: by Product, 2016–2024
Figure 71: Asia Pacific Biologics Market Attractiveness Analysis: by Applications, 2016–2024
Figure 72: Latin America Biologics Market Size (US$ Mn) Forecast, 2016–2024
Figure 73: Latin America Biologics Market Size and Y-o-Y Growth Projections, 2016–2024
Figure 74: Latin America Market Attractiveness Analysis: by Country
Figure 75: Latin America Biologics Market Value Share Analysis: by Product, 2016 and 2024
Figure 76: Latin America Biologics Market Value Share Analysis: by Applications, 2016 and 2024
Figure 77: Latin America Market Value Share Analysis: by Country, 2016 and 2024
Figure 78: Brazil Biologics Market Size (US$ Mn) Forecast, 2016-2024
Figure 79: Brazil Biologics Market Absolute $ Opportunity (US$ Mn), 2016-2024
Figure 80: Mexico Biologics Market Size (US$ Mn) Forecast, 2016-2024
Figure 81: Mexico Biologics Market Absolute $ Opportunity (US$ Mn), 2016-2024
Figure 82: Rest of LATAM Biologics Market Size (US$ Mn) Forecast, 2016-2024
Figure 83: Rest of LATAM Biologics Market Absolute $ Opportunity (US$ Mn), 2016-2024
Figure 84: Latin America Biologics Market Attractiveness Analysis: by Product, 2016–2024
Figure 85: Latin America Biologics Market Attractiveness Analysis: by Applications, 2016–2024
Figure 86: MEA Biologics Market Size (US$ Mn) and Volume (Units) Forecast, 2016–2024
Figure 87: MEA Biologics Market Size and Y-o-Y Growth Projections, 2016–2024
Figure 88: MEA Biologics Market Attractiveness Analysis: by Country
Figure 89: Middle East and Africa Biologics Market Value Share Analysis: by Product, 2016 and 2024
Figure 90: Middle East and Africa Biologics Market Value Share Analysis: by Applications, 2016 and 2024
Figure 91: MEA Biologics Market Value Share Analysis: by Country, 2016 and 2024
Figure 92: Saudi Arabia Biologics Market Size (US$ Mn) Forecast, 2016-2024
Figure 93: Saudi Arabia Biologics Market Absolute $ Opportunity (US$ Mn), 2016-2024
Figure 94: UAE Biologics Market Size (US$ Mn) Forecast, 2016-2024
Figure 95: UAE Biologics Market Absolute $ Opportunity (US$ Mn), 2016-2024
Figure 96: RSA Biologics Market Size (US$ Mn) Forecast, 2016-2024
Figure 97: RSA Biologics Market Absolute $ Opportunity (US$ Mn), 2016-2024
Figure 98: RSA Biologics Market Size (US$ Mn) Forecast, 2016-2024
Figure 99: RSA Biologics Market Absolute $ Opportunity (US$ Mn), 2016-2024
Figure 100: MEA Biologics Market Attractiveness Analysis: by Product, 2016–2024
Figure 101: MEA Biologics Market Attractiveness Analysis: by Applications, 2016–2024
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
*86 figures and 60 tables includes